137 related articles for article (PubMed ID: 33444077)
1. Comparative expression profile of CD10 and cyclin D1 in cutaneous histiocytofibroma and dermatofibrosarcoma.
Kouki N; Ben Rejeb S; Cherif I; Ghozzi A; Chelly I; Bellil K; Haouet S
J Immunoassay Immunochem; 2021 Jul; 42(4):347-358. PubMed ID: 33444077
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
3. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
[TBL] [Abstract][Full Text] [Related]
4. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
5. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
West KL; Cardona DM; Su Z; Puri PK
Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
[TBL] [Abstract][Full Text] [Related]
8. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans.
Kutzner H; Mentzel T; Palmedo G; Hantschke M; Rütten A; Paredes BE; Schärer L; Guillen CS; Requena L
Am J Surg Pathol; 2010 Feb; 34(2):190-201. PubMed ID: 20061935
[TBL] [Abstract][Full Text] [Related]
9. Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
Park S; Cho S; Kim M; Park JU; Jeong EC; Choi E; Park JH; Lee C; Chang MS
J Am Acad Dermatol; 2018 Nov; 79(5):843-852. PubMed ID: 29792909
[TBL] [Abstract][Full Text] [Related]
10. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.
Garcia C; Viehman G; Hitchcock M; Clark RE
Dermatol Surg; 1996 Feb; 22(2):177-9. PubMed ID: 8608381
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors.
Llombart B; Monteagudo C; Sanmartín O; López-Guerrero JA; Serra-Guillén C; Poveda A; Jorda E; Fernandez-Serra A; Pellín A; Guillén C; Llombart-Bosch A
J Am Acad Dermatol; 2011 Sep; 65(3):564-575. PubMed ID: 21570152
[TBL] [Abstract][Full Text] [Related]
12. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
13. Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas.
Szollosi Z; Scholtz B; Egervari K; Nemes Z
J Clin Pathol; 2007 Feb; 60(2):190-4. PubMed ID: 16731589
[TBL] [Abstract][Full Text] [Related]
14. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
Abdaljaleel MY; North JP
Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
[TBL] [Abstract][Full Text] [Related]
15. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
16. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
18. A pediatric case of dermatofibrosarcoma protuberans: an immunohistochemical study.
Patrizi A; Vespignani F; Fraternali GO; Neri I
Pediatr Dermatol; 2000; 17(1):29-33. PubMed ID: 10720984
[TBL] [Abstract][Full Text] [Related]
19. [Dermatofibrosarcoma Darier and Ferrand. Immunohistochemistry study of 38 cases. Research on a specific marker].
Declerck D; Claye C; Rotteleur G; Lecomte-Houcke M
Ann Pathol; 1997 Oct; 17(5):324-8. PubMed ID: 9471146
[TBL] [Abstract][Full Text] [Related]
20. Expression of the CD10 antigen (neutral endopeptidase) by mesenchymal tumors of the skin.
Kanitakis J; Bourchany D; Claudy A
Anticancer Res; 2000; 20(5B):3539-44. PubMed ID: 11131659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]